Can metabolic syndrome predict the vulnerable plaque in patients with stable angina pectoris? Virtual histology-intravascular ultrasound analysis

Journal of Cardiology

Volumn 59, Issue 3, 2012, Pages 266-274

  Lee, Min Goo ^a   Jeong, Myung Ho ^a   Kim, Dong Han ^a   Lee, Ki Hong ^a   Park, Keun Ho ^a   Sim, Doo Sun ^a   Yoon, Nam Sik ^a   Yoon, Hyun Ju ^a   Kim, Kye Hun ^a   Park, Hyung Wook ^a   Hong, Young Joon ^a   Kim, Ju Han ^a   Ahn, Youngkeun ^a   Cho, Jeong Gwan ^a   Park, Jong Chun ^a   Kang, Jung Chaee ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Angina pectoris; Metabolic syndrome; Vulnerable plaque

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROMA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HUMAN; INDEPENDENT VARIABLE; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; RETROSPECTIVE STUDY; STABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; ANGINA, STABLE; CHOLESTEROL, HDL; CORONARY ANGIOGRAPHY; CORONARY VESSELS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84862798105     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2011.11.003     Document Type: Article

References (36)

1. Burke A.P., Farb A., Malcom G.T., Liang Y.H., Smialek J., Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997, 336:1276-1282.
2. Burke A.P., Farb A., Malcom G.T., Liang Y.H., Smialek J., Virmani R. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation 1998, 97:2110-2116.
3. Kolodgie F.D., Burke A.P., Farb A., Gold H.K., Yuan J., Naruna J., Virmani R. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol 2001, 16:285-292.
4. Farb A., Tang A.L., Burke A.P., Sessums L., Liang Y.H., Virmani R. Sudden coronary death, frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation 1995, 92:1701-1709.
5. Virmani R., Kolodgie F.D., Burke A.P., Farb A., Schwartz S.M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000, 20:1262-1275.
6. Virmani R., Burke A.P., Farb A., Kolodgie F.D. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006, 47:C13-C18.
7. Hu G., Qiao Q., Tuomilehto J., Balkan B., Borch-Johnsen K., Pyörälä K. Prevalence of the metabolic syndrome and its relation to all cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004, 164:1066-1076. The DECODE Study Group.
8. Girman C.J., Rhodes T., Mercuri M., Pyörälä K., Kjekshus J., Pedersen T.R., Beere P.A., Gotto A.M., Clearfield M. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004, 93:136-141. The 4S group and the AFCAPS/TexCAPS research group.
9. Malik S., Wong N.D., Franklin S.S., Kamath T.V., L'Italien G.J., Pio J.R., Williams G.R. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110:1245-1250.
10. Saito I., Iso H., Kokubo Y., Inoue M., Tsugane S. Metabolic syndrome and all-cause and cardiovascular disease mortality: Japan public health center-based prospective (JPHC) study. Circ J 2009, 73:878-884.
11. Nair A., Kuban B.D., Tuzcu E.M., Schoenhagen P., Nissen S.E., Vince D.G. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002, 106:2200-2206.
12. Roberts W.L., Moulton L., Law T.C., Farrow G., Cooper-Anderson M., Savory J. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 2001, 47:418-425.
13. Mintz G.S., Nissen S.E., Anderson W.D., Bailey S.R., Erbel R., Fitzgerald P.J., Pinto F.J., Rosenfield K., Siegel R.J., Tuzcu E.M., Yock P.G. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS): a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001, 37:1478-1492.
14. Rodriguez-Granillo G.A., García-García H.M., Mc Fadden E.P., Vilgimigli M., Aoki J., de Feyter P., Serruys P.W. In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. J Am Coll Cardiol 2005, 46:2038-2042.
15. Schaar J.A., Muller J.E., Falk E., Virmani R., Fuster V., Serruys P.W., Colombo A., Stefanadis C., Casscells S.W., Moreno P.R., Maseri A., van der Steen A.F. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J 2004, 25:1077-1082.
16. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
17. Zakynthinos E., Pappa N. Inflammatory biomarkers in coronary artery disease. J Cardiol 2009, 53:317-333.
18. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
19. Marroquin O.C., Kip K.E., Kelley D.E., Johnson B.D., Shaw L.J., Bairey Merz C.N., Sharaf B.L., Pepine C.J., Sopko G., Reis S.E. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemic Syndrome Evaluation. Circulation 2004, 109:714-721. The Women's Ischemic Syndrome Evaluation.
20. Anderson J.L., Horne B.D., Jones H.U., Reyna S.P., Carlquist J.F., Bair T.L., Pearson R.R., Lappé D.L., Muhlestein J.B. Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease?. Cardiology 2004, 101:185-193.
21. Takeno M., Yasuda S., Otsuka Y., Morii I., Kawamura A., Yano K., Miyazaki S. Impact of metabolic syndrome on the long-term survival of patients with acute myocardial infarction: potential association with C-reactive protein. Circ J 2008, 72:415-419.
22. Dohi T., Miyaushi K., Kasai T., Kajimoto K., Kubota N., Tamura H., Yokohama T., Kojima T., Yokohama K., Kurata T., Daida H. Impact of metabolic syndrome on 10-year clinical outcomes among patients with acute coronary syndrome. Circ J 2009, 73:1454-1458.
23. Hong M.K., Mintz G.S., Lee C.W., Suh J., Kim J.H., Park D.W., Lee S.W., Kim Y.H., Cheong S.S., Kim J.J., Park S.W., Park S.J. Comparison of virtual histology to intravascular ultrasound of culprit coronary lesions in acute coronary syndrome and target coronary lesions in stable angina pectoris. Am J Cardiol 2007, 100:953-959.
24. Missel E., Mintz G.S., Carlier S.G., Sano K., Qian J., Kaple R.K., Castellanos C., Dangas G., Mehran R., Moses J.W., Stone G.W., Leon M.B. Necrotic core and its ratio to dense calcium are predictors of high-risk non-ST-elevation acute coronary syndrome. Am J Cardiol 2008, 101:573-578.
25. Stone G.W., Maehara A., Lansky A.J., de Bruyne B., Cristea E., Mintz G.S., Mehran R., McPherson J., Farhat N., Marso S.P., Parise H., Templin B., White R., Zhang Z., Serruys P.W., et al. A prospective natural-history study of coronary atherosclerosis. New Engl J Med 2011, 364:226-235.
26. Yamada R., Okura H., Kume T., Neishi Y., Kawamoto T., Miyamoto Y., Imai K., Saito K., Tsuchiya T., Hayashida A., Yoshida K. Target lesion thin-cap fibroatheroma defined by virtual histology intravascular ultrasound affects microvascular injury during percutaneous coronary intervention in patients with angina pectoris. Circ J 2010, 74:1658-1662.
27. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 2004, 95:764-772.
28. Sharrett A.R., Ballantyne C.M., Coady S.A., Heiss G., Sorlie P.D., Catellier D., Patsch W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoprotein A-1 and B, and HDL density subfractions: The atherosclerosis risk in communities (ARIC) study. Circulation 2001, 104:1108-1113.
29. Kato M., Dote K., Sasaki S., Ueda K., Kono Y., Naganuma T., Watanabe Y., Kajikawa M., Yokoyama H., Higashi A. Clinical impact of dyslipidemia for coronary plaque vulnerability in acute coronary syndrome without metabolic syndrome. J Cardiol 2009, 54:394-401.
30. Johnsen S.H., Mathiesen E.B., Fosse E., Joakimsen O., Stensland-Bugge E., Njølstad I., Arnesen E. Elevated high-density lipoprotein cholesterol levels are protective against plaque progression: a follow-up study of 1952 persons with carotid atherosclerosis. The Tromsø study. Circulation 2005, 112:498-504.
31. Wei L., Murphy M.J., MacDonald T.M. Impact on cardiovascular events of increasing high density lipoprotein cholesterol with and without lipid lowering drugs. Heart 2006, 92:746-751.
32. Olsson A.G., Schwartz G.G., Szarek M., Sasiela W.J., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005, 26:890-896.
33. Kastelein J.J.P. The realities of dyslipidemia: what do the studies tell us?. Eur Heart J 2005, 7(Suppl. F):F27-F33.
34. Brown B.G. Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy. Eur Heart J 2005, 7(Suppl. F):F34-F40.
35. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615-1622.
36. Gotto A.M., Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., Jou J.Y., Langendörfer A., Beere P.A., Watson D.J., Downs J.R., de Cani J.S. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000, 101:477-484.